Table 3.
Study sites with day 3 parasite positivity rate (PPR) >3 %
| Study site (country) | Year | Treatment | Day 3 PPR (95 % CI)a |
|---|---|---|---|
| New Halfa (Sudan) | 2006 | AL | 3.0 % (1/33) (0.5–15.3) |
| ELWA Hospital (Liberia) | 2007 | AL | 3.4 % (2/58) (0.9–11.7) |
| JFK Hospital (Liberia) | 2007 | AL | 3.8 % (2/53) (1.0–12.8) |
| Bagamoyo (Tanzania) | 2004 | AL | 4.0 % (2/50) (1.1–13.5) |
| Afokang (Nigeria) | 2007–08 | AL | 5.9 % (10/170) (3.2–10.5) |
| Ndumo (South Africa) | 2002 | AL | 6.0 % (6/100) (2.8–12.5) |
| San Pedro (Côte d’Ivoire) | 2012 | AL | 6.5 % (2/31) (1.8–20.7) |
| Gedaref (Sudan) | 2006 | AL | 7.8 % (4/51) (3.1–18.5) |
| Andapa (Madagascar) | 2007 | AS-AQ (loose NFDC) | 3.3 % (1/30) (0.6–16.7) |
| Gaya (Niger) | 2011 | AS-AQ (FDC) | 3.9 % (3/77) (1.3–10.8) |
| Grand Gedeh County (Liberia) | 2010–11 | AS-AQ (FDC) | 3.9 % (4/102) (1.5–9.7) |
| Dabola (Guinea) | 2004 | AS-AQ (loose NFDC) | 4.5 % (5/110) (1.9–10.2) |
| Afokang (Nigeria) | 2007–08 | AS-AQ (FDC) | 5.2 % (9/173) (2.8–9.6) |
| Malakal (Sudan) | 2003 | AS-AQ (loose NFDC) | 5.3 % (7/131) (2.6–10.6) |
| Kuito (Angola) | 2003 | AS-AQ (loose NFDC) | 5.4 % (5/93) (2.3–11.9) |
| Kailahun (Sierra Leone) | 2004 | AS-AQ (loose NFDC) | 5.6 % (7/125) (2.7–11.1) |
| Mlomp (Senegal) | 1999 | AS-AQ (loose NFDC) | 5.8 % (9/154) (3.1–10.7) |
| Richard Toll (Senegal) | 2003 | AS-AQ (loose NFDC) | 7.1 % (3/42) (2.5–19.0) |
| Miandrivazo (Madagascar) | 2006 | AS-AQ (loose NFDC) | 10.3 % (7/68) (5.1–19.8)b |
| Yaoundé (Cameroon) | 2005 | AS-AQ (coblistered NFDC) | 30.7 % (31/101) (22.5–40.3)b |
| Manhiça (Mozambique) | 2005–06 | DP | 4.0 % (12/299) (2.3–6.9) |
| Afokang (Nigeria) | 2007–08 | DP | 7.7 % (11/142) (4.4–13.3) |
aAssociated 95 % confidence interval computed using Wilson’s method; bthese sites have day 3 PPR >10 % and would be classed as sites with suspected partial artemisinin resistance requiring further investigation. Patients in Miandrivazo were treated with ASAQ-loose NFDC and those in Yaoundé treated with ASAQ-coblistered NFDC. AL, artemether-lumefantrine; AS-AQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; NFDC, non-fixed dose combination; PPR, parasite positivity rate